Pharmadule strengthens its presence in the Chinese market

As part of Pharmadule’s strategy to grow in Asia, the company today announced it has established access to production locally in the Chinese market. Through a partner agreement, Morimatsu Group has now been given rights to produce Pharmadule’s unique modular concept.

Pharmadule, the world leader in high-tech modular facilities for the pharmaceutical and biopharmaceutical industries today announced a partner agreement with Morimatsu Group. The agreement will give Morimatsu rights of manufacturing modules together with Pharmadule for the Chinese market. The cooperation supplements Pharmadule’s main production facility in Tallinn, Estonia. Morimatsu with long experience of providing tanks and equipment for the pharma, cosmetic, and food industry will provide Pharmadule with the right infrastructure and local presence. The company is Japanese but has, through 20 years of experience in the Chinese market, earned high reputation in the industry. The factory located in Shanghai, which is one of the pharmaceutical manufacturing clusters in China, will enable a rapid start of production. According to Lars Martinsson, CEO of Pharmadule, the company is pleased to have found a high performing and stable partner in China: “To serve the rapidly growing market in China, local presence is essential. We see a trend among our customers to expand in that area and Morimatsu provides an excellent opportunity for us. Our customers will now benefit by being able to use Pharmadule’s modular concept locally for investments in China”, says Lars Martinsson. Pharmadule's customer base is made up of a large number of repeat customers due to more than 20 years experience from the pharmaceutical and biopharmaceutical industries worldwide. The modular concept is known for bringing high predictability, rapid project execution, lowered risk and financial benefits to customers.